Cargando…

Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach

More than half of males in China are current smokers and evidence from western countries tells us that an unprecedented number of smoking-attributable deaths will occur as the Chinese population ages. We used the China Lung Cancer Policy Model (LCPM) to simulate effects of computed tomography (CT)-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheehan, Deirdre F., Criss, Steven D., Gazelle, G. Scott, Pandharipande, Pari V., Kong, Chung Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342219/
https://www.ncbi.nlm.nih.gov/pubmed/28273181
http://dx.doi.org/10.1371/journal.pone.0173119
_version_ 1782513131158765568
author Sheehan, Deirdre F.
Criss, Steven D.
Gazelle, G. Scott
Pandharipande, Pari V.
Kong, Chung Yin
author_facet Sheehan, Deirdre F.
Criss, Steven D.
Gazelle, G. Scott
Pandharipande, Pari V.
Kong, Chung Yin
author_sort Sheehan, Deirdre F.
collection PubMed
description More than half of males in China are current smokers and evidence from western countries tells us that an unprecedented number of smoking-attributable deaths will occur as the Chinese population ages. We used the China Lung Cancer Policy Model (LCPM) to simulate effects of computed tomography (CT)-based lung cancer screening in China, comparing the impact of a screening guideline published in 2015 by a Chinese expert group to a version developed for the United States by the U.S. Centers for Medicare & Medicaid Services (CMS). The China LCPM, built using an existing lung cancer microsimulation model, can project population outcomes associated with interventions for smoking-related diseases. After calibrating the model to published Chinese smoking prevalence and lung cancer mortality rates, we simulated screening from 2016 to 2050 based on eligibility criteria from the CMS and Chinese guidelines, which differ by age to begin and end screening, pack-years smoked, and years since quitting. Outcomes included number of screens, mortality reduction, and life-years saved for each strategy. We projected that in the absence of screening, 14.98 million lung cancer deaths would occur between 2016 and 2050. Screening with the CMS guideline would prevent 0.72 million deaths and 5.8 million life-years lost, resulting in 6.58% and 1.97% mortality reduction in males and females, respectively. Screening with the Chinese guideline would prevent 0.74 million deaths and 6.6 million life-years lost, resulting in 6.30% and 2.79% mortality reduction in males and females, respectively. Through 2050, 1.43 billion screens would be required using the Chinese screening strategy, compared to 988 million screens using the CMS guideline. In conclusion, CT-based lung cancer screening implemented in 2016 and based on the Chinese screening guideline would prevent about 20,000 (2.9%) more lung cancer deaths through 2050, but would require about 445 million (44.7%) more screens than the CMS guideline.
format Online
Article
Text
id pubmed-5342219
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-53422192017-03-29 Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach Sheehan, Deirdre F. Criss, Steven D. Gazelle, G. Scott Pandharipande, Pari V. Kong, Chung Yin PLoS One Research Article More than half of males in China are current smokers and evidence from western countries tells us that an unprecedented number of smoking-attributable deaths will occur as the Chinese population ages. We used the China Lung Cancer Policy Model (LCPM) to simulate effects of computed tomography (CT)-based lung cancer screening in China, comparing the impact of a screening guideline published in 2015 by a Chinese expert group to a version developed for the United States by the U.S. Centers for Medicare & Medicaid Services (CMS). The China LCPM, built using an existing lung cancer microsimulation model, can project population outcomes associated with interventions for smoking-related diseases. After calibrating the model to published Chinese smoking prevalence and lung cancer mortality rates, we simulated screening from 2016 to 2050 based on eligibility criteria from the CMS and Chinese guidelines, which differ by age to begin and end screening, pack-years smoked, and years since quitting. Outcomes included number of screens, mortality reduction, and life-years saved for each strategy. We projected that in the absence of screening, 14.98 million lung cancer deaths would occur between 2016 and 2050. Screening with the CMS guideline would prevent 0.72 million deaths and 5.8 million life-years lost, resulting in 6.58% and 1.97% mortality reduction in males and females, respectively. Screening with the Chinese guideline would prevent 0.74 million deaths and 6.6 million life-years lost, resulting in 6.30% and 2.79% mortality reduction in males and females, respectively. Through 2050, 1.43 billion screens would be required using the Chinese screening strategy, compared to 988 million screens using the CMS guideline. In conclusion, CT-based lung cancer screening implemented in 2016 and based on the Chinese screening guideline would prevent about 20,000 (2.9%) more lung cancer deaths through 2050, but would require about 445 million (44.7%) more screens than the CMS guideline. Public Library of Science 2017-03-08 /pmc/articles/PMC5342219/ /pubmed/28273181 http://dx.doi.org/10.1371/journal.pone.0173119 Text en © 2017 Sheehan et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Sheehan, Deirdre F.
Criss, Steven D.
Gazelle, G. Scott
Pandharipande, Pari V.
Kong, Chung Yin
Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach
title Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach
title_full Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach
title_fullStr Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach
title_full_unstemmed Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach
title_short Evaluating lung cancer screening in China: Implications for eligibility criteria design from a microsimulation modeling approach
title_sort evaluating lung cancer screening in china: implications for eligibility criteria design from a microsimulation modeling approach
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342219/
https://www.ncbi.nlm.nih.gov/pubmed/28273181
http://dx.doi.org/10.1371/journal.pone.0173119
work_keys_str_mv AT sheehandeirdref evaluatinglungcancerscreeninginchinaimplicationsforeligibilitycriteriadesignfromamicrosimulationmodelingapproach
AT crissstevend evaluatinglungcancerscreeninginchinaimplicationsforeligibilitycriteriadesignfromamicrosimulationmodelingapproach
AT gazellegscott evaluatinglungcancerscreeninginchinaimplicationsforeligibilitycriteriadesignfromamicrosimulationmodelingapproach
AT pandharipandepariv evaluatinglungcancerscreeninginchinaimplicationsforeligibilitycriteriadesignfromamicrosimulationmodelingapproach
AT kongchungyin evaluatinglungcancerscreeninginchinaimplicationsforeligibilitycriteriadesignfromamicrosimulationmodelingapproach